258 related articles for article (PubMed ID: 25090288)
1. The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma.
Cheung P; Thibault I; Bjarnason GA
Curr Opin Support Palliat Care; 2014 Sep; 8(3):258-64. PubMed ID: 25090288
[TBL] [Abstract][Full Text] [Related]
2. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.
Siva S; Kothari G; Muacevic A; Louie AV; Slotman BJ; Teh BS; Lo SS
Nat Rev Urol; 2017 Sep; 14(9):549-563. PubMed ID: 28631740
[TBL] [Abstract][Full Text] [Related]
4. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy for oligoprogressive cancer.
Cheung P
Br J Radiol; 2016 Oct; 89(1066):20160251. PubMed ID: 27556349
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative body radiotherapy for lung cancer.
Franks KN; Jain P; Snee MP
Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
8. New Strategies in Stereotactic Radiotherapy for Oligometastases.
Palma DA; Louie AV; Rodrigues GB
Clin Cancer Res; 2015 Dec; 21(23):5198-204. PubMed ID: 26626571
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
[TBL] [Abstract][Full Text] [Related]
10. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
[TBL] [Abstract][Full Text] [Related]
11. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
12. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease.
Alongi F; Arcangeli S; Triggiani L; Mazzola R; Buglione di Monale E Bastia M; Fersino S; Baiguini A; Jereczek-Fossa BA; Magrini SM;
Crit Rev Oncol Hematol; 2017 Sep; 117():48-56. PubMed ID: 28807235
[TBL] [Abstract][Full Text] [Related]
14. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
19. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.
Saluja R; Cheung P; Zukotynski K; Emmenegger U
Urol Oncol; 2016 May; 34(5):225-32. PubMed ID: 27008982
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
